Amneal Pharmaceuticals (AMRX) Non-Current Deferred Tax Liability (2017 - 2018)
Amneal Pharmaceuticals (AMRX) posted quarterly Non-Current Deferred Tax Liability of $1.2 million for Q4 2018, down 64.16% year-over-year from $3.3 million in Q4 2017, and down 33.11% quarter-over-quarter from $1.8 million in Q3 2018.
Amneal Pharmaceuticals (AMRX) Non-Current Deferred Tax Liability (2017 - 2018) Analysis & Trends
Amneal Pharmaceuticals' Non-Current Deferred Tax Liability history runs 2 years deep, the most recent figure standing at $1.2 million for Q4 2018.
- In Q4 2018, Non-Current Deferred Tax Liability fell 64.16% year-over-year to $1.2 million; the TTM figure through Dec 2018 stood at $1.2 million (down 64.16% YoY), while the FY2018 annual figure was $1.2 million, down 64.16% from the prior year.
- Non-Current Deferred Tax Liability for Q4 2018 stood at $1.2 million, down from $1.8 million in the prior quarter.
- The five-year high for Non-Current Deferred Tax Liability was $3.3 million in Q4 2017, with the low at $1.2 million in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | Amneal Pharmaceuticals | 5.72 Bn | 5.59 Bn | 334.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 1.18 Mn |
| Dec 31, 2018 | 1.18 Mn |
| Sep 30, 2018 | 1.76 Mn |
| Sep 30, 2018 | 1.76 Mn |
| Jun 30, 2018 | 2.49 Mn |
| Jun 30, 2018 | 2.49 Mn |
| Dec 31, 2017 | 3.29 Mn |
| Dec 31, 2017 | 3.29 Mn |